NDC-11 (Package) | NDC-9 (Product) | Generic Name (Ascending) | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
31722-0259-01 | 31722-0259 | LENALIDOMIDE | LENALIDOMIDE | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
31722-0259-28 | 31722-0259 | LENALIDOMIDE | LENALIDOMIDE | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
31722-0260-01 | 31722-0260 | LENALIDOMIDE | LENALIDOMIDE | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
31722-0260-21 | 31722-0260 | LENALIDOMIDE | LENALIDOMIDE | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
31722-0261-01 | 31722-0261 | LENALIDOMIDE | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
31722-0261-21 | 31722-0261 | LENALIDOMIDE | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
31722-0262-01 | 31722-0262 | LENALIDOMIDE | LENALIDOMIDE | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
31722-0262-21 | 31722-0262 | LENALIDOMIDE | LENALIDOMIDE | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
70710-1030-01 | 70710-1030 | LENALIDOMIDE | LENALIDOMIDE | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | March 7, 2023 | In Use | |
70710-1030-07 | 70710-1030 | LENALIDOMIDE | LENALIDOMIDE | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | March 7, 2023 | In Use | |
70710-1034-01 | 70710-1034 | LENALIDOMIDE | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | March 7, 2023 | In Use | |
70710-1034-08 | 70710-1034 | LENALIDOMIDE | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | March 7, 2023 | In Use | |
70771-1676-01 | 70771-1676 | LENALIDOMIDE | LENALIDOMIDE | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | March 7, 2023 | In Use | |
70771-1676-07 | 70771-1676 | LENALIDOMIDE | LENALIDOMIDE | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | March 7, 2023 | In Use | |
70771-1680-01 | 70771-1680 | LENALIDOMIDE | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | March 7, 2023 | In Use | |
70771-1680-08 | 70771-1680 | LENALIDOMIDE | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | March 7, 2023 | In Use | |
76282-0696-48 | 76282-0696 | LENALIDOMIDE | LENALIDOMIDE | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | June 10, 2024 | In Use | |
67457-0530-35 | 67457-0530 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 350.0 mg/17.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Jan. 2, 2019 | In Use | |
71205-0908-00 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 16, 2021 | In Use | |
71205-0908-11 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 16, 2021 | In Use | |
71205-0908-30 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 16, 2021 | In Use | |
71205-0908-55 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 16, 2021 | In Use | |
71205-0908-60 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 16, 2021 | In Use | |
71205-0908-90 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | July 16, 2021 | In Use | |
67457-0528-10 | 67457-0528 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 100.0 mg/10mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | July 23, 2019 | In Use | |
67457-0529-20 | 67457-0529 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 200.0 mg/20mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | July 23, 2019 | In Use | |
69448-0014-63 | 69448-0014 | LEUPROLIDE | CAMCEVI | 42.0 mg/.37g | Hormonal Therapy | GnRH Agonist | Subcutaneous | April 5, 2022 | In Use | ||
55150-0478-01 | 55150-0478 | LEUPROLIDE ACETATE | LEUPROLIDE ACETATE | Hormonal Therapy | GnRH Agonist | June 6, 2022 | In Use | ||||
43598-0771-11 | 43598-0771 | LEVOLEUCOVORIN | LEVOLEUCOVORIN | 175.0 mg/17.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Sept. 26, 2018 | In Use | |
43598-0773-11 | 43598-0773 | LEVOLEUCOVORIN | LEVOLEUCOVORIN | 250.0 mg/25mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Sept. 26, 2018 | In Use | |
16714-0915-01 | 16714-0915 | LEVOLEUCOVORIN | LEVOLEUCOVORIN | 250.0 mg/25mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Sept. 26, 2018 | In Use | |
16714-0890-01 | 16714-0890 | LEVOLEUCOVORIN | LEVOLEUCOVORIN | 175.0 mg/17.5mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | Sept. 26, 2018 | In Use | |
15054-0060-01 | 15054-0060 | Lanreotide acetate | Somatuline Depot | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov. 14, 2007 | Aug. 31, 2016 | No Longer Used | |
15054-0090-01 | 15054-0090 | Lanreotide acetate | Somatuline Depot | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov. 14, 2007 | Aug. 31, 2016 | No Longer Used | |
15054-0120-01 | 15054-0120 | Lanreotide acetate | Somatuline Depot | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov. 14, 2007 | Aug. 31, 2016 | No Longer Used | |
15054-1060-03 | 15054-1060 | Lanreotide acetate | Somatuline Depot | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov. 14, 2007 | June 30, 2022 | In Use | |
15054-1060-04 | 15054-1060 | Lanreotide acetate | Somatuline Depot | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Sept. 1, 2019 | In Use | ||
15054-1090-03 | 15054-1090 | Lanreotide acetate | Somatuline Depot | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov. 14, 2007 | June 30, 2022 | In Use | |
15054-1090-04 | 15054-1090 | Lanreotide acetate | Somatuline Depot | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Sept. 1, 2019 | In Use | ||
15054-1120-03 | 15054-1120 | Lanreotide acetate | Somatuline Depot | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov. 14, 2007 | June 30, 2022 | In Use | |
15054-1120-04 | 15054-1120 | Lanreotide acetate | Somatuline Depot | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Sept. 1, 2019 | In Use | ||
69097-0870-67 | 69097-0870 | Lanreotide acetate | Lanreotide Acetate | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Dec. 24, 2021 | In Use | ||
69097-0880-67 | 69097-0880 | Lanreotide acetate | Lanreotide Acetate | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Dec. 24, 2021 | In Use | ||
69097-0890-67 | 69097-0890 | Lanreotide acetate | Lanreotide Acetate | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Dec. 24, 2021 | In Use | ||
76282-0709-67 | 76282-0709 | Lanreotide acetate | Lanreotide Acetate | 60.0 mg/.2mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | June 1, 2022 | Aug. 18, 2023 | In Use | |
76282-0710-67 | 76282-0710 | Lanreotide acetate | Lanreotide Acetate | 90.0 mg/.3mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | June 1, 2022 | Aug. 18, 2023 | In Use | |
76282-0711-67 | 76282-0711 | Lanreotide acetate | Lanreotide Acetate | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | June 1, 2022 | Aug. 18, 2023 | In Use | |
00078-0671-19 | 00078-0671 | Lapatinib | TYKERB | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Aug. 3, 2016 | In Use | |
00173-0752-00 | 00173-0752 | Lapatinib | TYKERB | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | March 16, 2007 | Nov. 30, 2017 | No Longer Used |
59572-0402-00 | 59572-0402 | Lenalidomide | Revlimid | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 9, 2012 | In Use |
Found 10,000 results in 9 milliseconds — Export these results